A Study of Chemotherapy Treatment for Patients With Ovarian Cancer
Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
The primary objective is to determine whether LY573636-sodium (hereafter referred to as
LY573636) is effective in treating platinum-resistant ovarian cancer. Patients will receive
an intravenous infusion of study drug once every 28 days. Computed tomography (CT) scans and
CA-125 tests will be done before the first dose and then after every other treatment.